investor.sagerx.com – Funding, Valuation, Investors, News

Startups

Edit

http://investor.sagerx.com/

Last activity: 14.12.2023

Active

Categories: BusinessFinTechInformationWebsite

The Investor Relations website contains information about Sage Therapeutics, Inc.'s business for stockholders, potential investors, and financial analysts.

Instagram Email

Website visits

4.6K /mo.

Mentions

Mentions in press and media 23

Date	Title	Description
Sign up to see	Sign up to see	Sign up to see
Nov 7, 2023	Your morning biotech news roundup	Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Good morning, everyone. Damian here with a CRISPR delay, some curious biotech language, and the derailment of a prom...
Aug 8, 2023	Impact of new pill to treat postpartum depression will depend on price	The approval of the first-ever pill treating postpartum depression on Friday was hailed as a significant milestone, but it was quickly tempered by questions around how much the drug will cost. Why it matters: The price of zuranolone will ul...
Aug 4, 2023	FDA approves zuranolone, first pill for postpartum depression	The Food and Drug Administration announced Friday it has approved the first oral treatment for postpartum depression. The drug, called zuranolone, is a once-a-day pill that will be branded as Zurzuvae by drugmakers Sage Therapeutics and Bio...
Jul 27, 2023	Postpartum depression pill zuranolone yields "significant improvements," clinical trial data shows	A pill being developed to treat postpartum depression is showing promise for new parents who suffer from the condition, according to newly released clinical trial data. The study, published Wednesday in The American Journal of Psychiatry, f...
Feb 13, 2023	The top doctor at a $2.7 billion pharma company developing a new depression drug says we may be 'on the cusp' of a new wave of mental-health treatments	Sad young woman sitting on the window, watching out - stock photo Tunatura/Getty Images Redeem now Most depression treatments don't work quickly and are meant to be taken for long periods of time. Sage Therapeutics is developing a fast-acti...
Feb 2, 2023	Depression treatments haven't changed much in decades. Here are the promising new drugs that could be more precise, work faster, and help more people.	Getty Images Advances in depression treatment have been rare over the past few decades. But biotech companies are looking for ways to improve treatments. While some are developing drugs that work faster, others are targeting subtypes of the...
Feb 16, 2022	Sage Antidepressant Trial Hits Its Target. Why the Stock Is Down.	Sage Therapeutics and Biogen disclosed the results of a trial of their experimental depression drug zuranolone, saying the data showed that it sped up reduction of depression symptoms when begun alongside a standard-of-care antidepressant. ...
Aug 3, 2021	Going so soon? Scholar Rock CEO makes swift exit, leaving Nagesh Mahanthappa back at the helm	Tony Kingsley Just over a year after taking the helm at Cambridge, MA-based Scholar Rock — and just as the company prepares to send its lead spinal muscular atrophy candidate to Phase III — CEO Tony Kingsley is already on hi...
Aug 3, 2021	Sage drops a pair of late-stage tests for Biogen-partnered depression drug, raising the stakes on a final trial	BeiGene has made its presence in the US known with the FDA approval of its oncology treatment two years ago, and its five offices across the country. Tuesday, the company announced that it will add a sixth location, this time an R&D and...
Aug 3, 2021	Sage drops a pair of late-stage tests for Biogen-partnered depression drug, raising the stakes on a final trial	When Sage Therapeutics’ star experimental depression drug, zuranolone, failed the crucial MOUNTAIN study, the biotech slammed the brakes on two other pivotal trials in order to rethink their design. Now that a second Pha...
Aug 3, 2021	Roche's PD-L1 franchise player nabs priority review; One of world's first psychedelics research institutes opens in Australia	The FDA has just put Genentech’s latest shot at adding blockbuster sales for Tecentriq on the regulator’s inside track. Roche said Tuesday that the agency has provided priority review status for a supplemental NDA to get ...
Aug 3, 2021	Roche's PD-L1 franchise player nabs priority review; One of world's first psychedelics research institutes opens in Australia	Sanofi CEO Paul Hudson is dead serious about his intention to vault directly into contention for the future of mRNA vaccines. A year after paying Translate Bio $TBIO a whopping $425 million in an upfront and equity payment to help guide the...
Aug 3, 2021	J&J, GV back a new single-cell approach for tackling inflammatory diseases and hacking the tumor microenvironment	Most biotechs trying to tackle inflammatory disorders like IBD or attempting to boost the potency of immunotherapies for cancer have focused, logically, on targeting, blocking or redirecting immune cells. J&J, ...
Aug 2, 2021	Bristol Myers pulls lymphoma indication for Istodax after confirmatory trial falls flat	Amid an industrywide review of cancer drugs with accelerated approval, Bristol Myers Squibb had to make the tough call last month to yank an approval for leading I/O drug Opdivo after flopping a confirmatory study. Now...
Mar 18, 2020	Sage plots comeback plan for its experimental oral antidepressant	Trials testing depression drugs invariably tend to disappoint. Perhaps the most keenly-anticipated depression trial of 2019, despite great analyst and investor optimism, also failed in patients with major depress...
Dec 5, 2019	Sage Therapeutics’ stock tanks as Phase III depression study misses primary endpoint	Shares of a company developing a drug to treat depression dropped sharply Thursday following the announcement that its registration-directed clinical trial had missed its primary endpoint. Cambridge, Massachusetts-based Sage Therapeutics sa...
May 30, 2018	FDA moves Sage’s postpartum depression drug brexanolone into regulators’ busy priority lane	The FDA’s priority review pathway is getting a workout. Regulators agreed to give Sage Therapeutics $SAGE a quick 6-month review for IV brexanolone (SAGE-547) — the FDA’s third priority move in two days — which it hopes wi...
Apr 23, 2018	Sage files for an approval for its ‘breakthrough’ therapy for postpartum depression	Sage Therapeutics $SAGE is rolling the dice on their “breakthrough” drug for postpartum depression. The Cambridge, MA-based biotech has filed for an FDA approval of brexanolone IV, pitching the therapy in a shot at its first e...
Sep 12, 2017	Sage’s quick flip into PhIII crashes as lead drug fails badly for rare type of seizures	After building intense interest in its lead drug for super-refractory status epilepticus with data from tiny studies, Sage Therapeutics $SAGE says the drug failed badly in Phase III. Comparing brexanolone (SAGE-547) wit...
Feb 17, 2017	Sage CEO’s M&A chatter sparks a spike, and an awkward correction	Few biotech CEOs like to hype data from tiny studies quite as much as an enthusiastic Jeff Jonas at Sage $SAGE. But on Thursday, he pumped it a little too hard. Doni Bloomfield from Bloomberg taped him for a segment on the Bay Sta...
	Sage Therapeutics’ stock tanks as Phase III depression study misses primary endpoint	Shares of a company developing a drug to treat depression dropped sharply Thursday following the announcement that its registration-directed clinical trial had missed its primary endpoint. Cambridge, Massachusetts-based Sage Therapeutics sa...
	Sage Therapeutics Announces Fourth Quarter and Full Year 2020 Financial Results and Highlights Pipeline and Business Progress	CAMBRIDGE, Mass.--(BUSINESS WIRE)--Feb 24, 2021-- Today, Sage Therapeutics, Inc. (NASDAQ: SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating disor...

Mentions in press and media 23

Reviews 0